Potential cancer risk with omalizumab: a disproportionality analysis of
the WHO’s VigiBase pharmacovigilance database
- Diogo Mota,
- Tiago Rama,
- Milton Severo,
- André Moreira
Tiago Rama
Faculdade de Medicina da Universidade do Porto, Porto, Portugal & Centro Hospitalar São João
Author Profile10 Apr 2021Submitted to Allergy 12 Apr 2021Submission Checks Completed
12 Apr 2021Assigned to Editor
13 Apr 2021Reviewer(s) Assigned
25 Apr 2021Review(s) Completed, Editorial Evaluation Pending
29 May 20211st Revision Received
31 May 2021Submission Checks Completed
31 May 2021Assigned to Editor
01 Jun 2021Reviewer(s) Assigned
04 Jun 2021Review(s) Completed, Editorial Evaluation Pending
15 Jun 2021Editorial Decision: Revise Minor
